06.05.2024 • News • Neste • People

Neste Appoints Heikki Malinen as President and CEO

Neste has appointed Heikki Malinen as president and CEO of Neste, effective Nov. 2, 2024, at the latest. He succeeds Matti Lehmus, who decided to leave the company. Malinen is currently a member of Neste’s board of directors, but will step down before taking up his new role.

As the company announced on Apr. 29, 2024, the current president and CEO of Neste, Matti Lehmus, will step down but will continue in his position until Heikki Malinen takes over.

Malinen joins Neste from Outokumpu where he was president and CEO since 2020. Prior to that, he worked for Posti Group, Pöyry, and UPM-Kymmene in leadership roles. He holds an M.Sc. (Econ.) Helsinki School of Economics and an MBA from Harvard Business School.

Neste has appointed Heikki Malinen as president and CEO of Neste. © Neste
Neste has appointed Heikki Malinen as president and CEO of Neste. © Neste

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.